Novo Nordisk (NVO) Nosedives 22% on Lower Growth Outlook, New CEO Appointment

We recently published Massive Drop Alert: These 10 Stocks Take a Beating. Novo Nordisk A/S (NYSE:NVO) is one of the worst-performing stocks on Tuesday.

Novo Nordisk fell by 21.83 percent on Tuesday to end at $53.94 apiece as investors unloaded positions following the company’s pessimistic outlook for the rest of the year and the naming of a new chief executive.

In a statement, Novo Nordisk A/S (NYSE:NVO) said it now expects full-year sales to grow between 8 and 14 percent, down from the 13 to 21 percent projected previously, as well as annual operating income growth to slow down at 10 to 16 percent as compared with the 16 to 24 percent prior.

Novo Nordisk A/S (NYSE:NVO) said the new guidance was due to an expected weaker second half sales growth forecast for its blockbuster Wegovy and Ozempic drugs.

“For Wegovy in the US, the sales outlook reflects the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition,” Novo Nordisk A/S (NYSE:NVO).

Meanwhile, the company welcomed company veteran Maziar Mike Doustdar as its new CEO, effective August 7, 2025 who will replace ousted CEO Lars Fruergaard Jørgensen.

While we acknowledge the potential of NVO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.